Date: 2013-05-23
Type of information: R&D agreement
Compound: predictive biomarkers
Company: Cenix BioScience (USA) Debiopharm (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
development
Action mechanism:
Disease:
Details: * On May 23, 2013, Cenix BioScience, a preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.
Under the research framework’s first project, Cenix will apply its leading expertise in combining high throughput screening with high content assays in cultured human cells, to identify predictive biomarkers for Debiopharm preclinical oncology candidates. Multi-parametric microscopy-based readouts established by Cenix using the Definiens XD image analysis platform will be used in a range of human cancer cell models to identify genes and pathways that either enhance or suppress the drug’s therapeutic effects. As such, the study represents another important illustration of Debiopharm’s ongoing drive to integrate cutting edge technologies and powerful post-genomic strategies towards further refining its personalized medicine approach towards the development of new therapeutics.
Financial terms:
Latest news:
